(2,3,5,6-tetrafluoro-4-methoxymethylphenyl)methyl-2,2-dimethyl-3-(1-propenyl)cyclopropanecarboxylate: pyrethroid active against mosquitoes; metofluthrin is the (1R,3R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5282227 |
| CHEBI ID | 79396 |
| SCHEMBL ID | 24119147 |
| MeSH ID | M0474538 |
| Synonym |
|---|
| metofluthrin |
| metofluthrin (jan) |
| D01988 |
| 240494-70-6 |
| [2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 2,2-dimethyl-3-[(e)-prop-1-enyl]cyclopropane-1-carboxylate |
| matofluthrin |
| (2,3,5,6-tetrafluoro-4-methoxymethylphenyl)methyl-2,2-dimethyl-3-(1-propenyl)cyclopropanecarboxylate |
| sumione |
| unii-wzx356s299 |
| hsdb 7885 |
| metofluthrin [iso] |
| wzx356s299 , |
| eminence |
| CHEBI:79396 |
| [2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 2,2-dimethyl-3-[(e)-prop-1-enyl]cyclopropanecarboxylate |
| KVIZNNVXXNFLMU-AATRIKPKSA-N |
| [2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 2,2-dimethyl-3-pro p-1-enyl-cyclopropane-1-carboxylate |
| cyclopropanecarboxylic acid, 2,2-dimethyl-3-(1-propen-1-yl)-, [2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl ester |
| SCHEMBL24119147 |
| 1ST20600 |
Metofluthrin is a newly synthesized pyrethroid possessing high knockdown and lethal activity against mosquitoes.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Metofluthrin is a newly synthesized pyrethroid possessing high knockdown and lethal activity against mosquitoes. " | ( Field evaluation of spatial repellency of metofluthrin-impregnated plastic strips against Anopheles gambiae complex in Bagamoyo, coastal Tanzania. Iwasaki, T; Kawada, H; Matsumoto, O; Minjas, JN; Takagi, M; Temu, EA, 2008) | 2.05 |
| "Metofluthrin (SumiOne is a novel, vapor-active pyrethroid that is highly effective against mosquitoes. " | ( U.S. laboratory and field trials of metofluthrin (SumiOne) emanators for reducing mosquito biting outdoors. Benzon, G; Ishiwatari, T; Iwasaki, T; Lucas, JR; Shono, Y; Spero, N, 2007) | 2.06 |
Metofluthrin has a great potential as a supporting ingredient to other insecticides. It has extremely high insecticidal activity to various pest insects, especially mosquitoes.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Metofluthrin has a great potential as a supporting ingredient to other insecticides." | ( Comparative Evaluation of Metofluthrin as an Outdoor Residual Treatment for Barriers and Harborage Against Aedes albopictus (Diptera: Culicidae). Bibbs, CS; Kaufman, PE; Xue, RD, 2020) | 1.58 |
| "Metofluthrin has a great potential as a supporting ingredient to other insecticides." | ( Comparative Evaluation of Metofluthrin as an Outdoor Residual Treatment for Barriers and Harborage Against Aedes albopictus (Diptera: Culicidae). Bibbs, CS; Kaufman, PE; Xue, RD, 2020) | 1.58 |
| "Metofluthrin has extremely high insecticidal activity to various pest insects, especially to mosquitoes." | ( The biological activity of a novel pyrethroid: metofluthrin. Ishiwatari, T; Sugano, M, 2012) | 1.36 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Metofluthrin did not cause cytotoxicity or peroxisome proliferation." | ( Mode of action analysis for the synthetic pyrethroid metofluthrin-induced rat liver tumors: evidence for hepatic CYP2B induction and hepatocyte proliferation. Deguchi, Y; Hirose, Y; Kawamura, S; Kushida, M; Nagahori, H; Nishioka, K; Okuno, Y; Sukata, T; Sumida, K; Tomigahara, Y; Uwagawa, S; Yamada, T, 2009) | 1.32 |
Metofluthrin treatments resulted in a 50-90% reduction of eggs collected for 4 wk up to 60 m away from treated vegetation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Metofluthrin treatments resulted in a 50-90% reduction of eggs collected for 4 wk up to 60 m away from treated vegetation." | ( Comparative Evaluation of Metofluthrin as an Outdoor Residual Treatment for Barriers and Harborage Against Aedes albopictus (Diptera: Culicidae). Bibbs, CS; Kaufman, PE; Xue, RD, 2020) | 1.58 |
| "The metofluthrin dose for each treatment group of male and female Ae. " | ( Effects of sublethal exposure to metofluthrin on the fitness of Aedes aegypti in a domestic setting in Cairns, Queensland. Buhagiar, TS; Devine, GJ; Ritchie, SA, 2017) | 1.29 |
| "Metofluthrin treatment reduced mosquito collection by >80% during the 1st 4 weeks." | ( Laboratory and field evaluation of spatial repellency with metofluthrin-impregnated paper strip against mosquitoes in Lombok Island, Indonesia. Kawada, H; Maekawa, Y; Takagi, M; Tsuda, Y, 2004) | 1.29 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Such information will facilitate identifying the optimum active ingredient (AI) dosage and intervention coverage important for the development of spatial repellent tools--one of several novel strategies being evaluated for vector-borne disease control." | ( Identifying the effective concentration for spatial repellency of the dengue vector Aedes aegypti. Achee, N; Chareonviryiphap, T; Grieco, J; Hendarto, J; Martin, N; Masuoka, P; Polsomboon, S; Smith, P, 2012) | 0.38 |
| Class | Description |
|---|---|
| carboxylic ester | An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (26.00) | 29.6817 |
| 2010's | 28 (56.00) | 24.3611 |
| 2020's | 9 (18.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.81) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (4.00%) | 5.53% |
| Reviews | 1 (2.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 47 (94.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||